Enliven Therapeutics (ELVN) Share-based Compensation (2019 - 2026)

Enliven Therapeutics has disclosed Share-based Compensation across 8 years of filings, most recently posting $7.4 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $7.4 million, up 8.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.6 million (up 54.14% YoY), and the FY2025 annual result was $34.0 million, up 68.63% from the prior year.
• Share-based Compensation came in at $7.4 million for Q1 2026 at Enliven Therapeutics, down from $12.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $12.3 million in Q4 2025 to a low of $654000.0 in Q1 2022.
• The 5-year median for Share-based Compensation is $4.5 million (2024), against an average of $4.6 million.
• Across the five-year window, Share-based Compensation sank 30.94% in 2022 and soared 498.43% in 2023, its largest moves.
• Enliven Therapeutics' Share-based Compensation stood at $735000.0 in 2022, then jumped by 315.78% to $3.1 million in 2023, then surged by 74.71% to $5.3 million in 2024, then jumped by 130.59% to $12.3 million in 2025, then plunged by 39.92% to $7.4 million in 2026.
• The last three Share-based Compensation figures came in at $7.4 million (Q1 2026), $12.3 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.